Company news

Halozyme Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference

February 25, 2020

Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology

February 24, 2020

Halozyme Reports Fourth Quarter and Full Year 2019 Results

February 23, 2020

Halozyme Announces CFO Transition

February 23, 2020

Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call

February 9, 2020

Halozyme Provides 2020 Business Update And Financial Guidance

January 13, 2020

Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference

January 2, 2020

Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium

December 11, 2019

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

November 12, 2019

Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024

November 11, 2019

Halozyme Reports Third Quarter 2019 Results

November 11, 2019

Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint

November 3, 2019

Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology

November 3, 2019

Halozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call

October 20, 2019

Halozyme To Participate In 2019 Cantor Global Healthcare Conference

September 22, 2019

Halozyme Reports Second Quarter 2019 Results

August 5, 2019

Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call

July 22, 2019

Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

July 18, 2019

Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology

July 16, 2019

Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

July 11, 2019

Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology

June 24, 2019

Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

May 21, 2019

Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call

April 22, 2019

← Newer news releases

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 66 decks. Every deck is listed under its year.